An off-switch for drugs' toxic side effects

Jun 20, 2014 by Angela Herring
Professor Alexandros Makriyannis and his team in the Center for Drug Discovery at Northestern have developed a series of drug compounds that are programmed to break down at a specific time. Credit: Mary Knox Merrill

When medications linger in the human body, they sometimes produce toxic side effects.

Professor Alexandros Makriyannis, the George D. Behrakis Trustee Chair in Pharmaceutical Biotechnology and Director of the Center for Drug Discovery at Northeastern, explained that many things can happen to a drug inside our bodies once it is ingested. For instance, the drug can be modified into other byproducts with their own undesirable and unpredictable effects. Or it can remain embedded in the body's fatty tissues and then be slowly released into the circulatory system.

"If you had a way of controlling how long this drug sits in the body," Makriyannis said, "that would be a beneficial . It would be a safer drug."

In research recently published in the Journal of Medicinal Chemistry and Medicinal Chemistry Letters, Makriyannis and his team present not just one such drug but a whole series of them. "We call this concept controlled deactivation," he explained.

In this research, Makriyannis' team presents more than 100 compounds that are variants of drugs the researchers previously patented. These target the endocannabinoid system, which includes receptors within the surface of cells throughout our bodies that are responsible for functions like pain, mood, memory, and appetite modulation.

The original versions of the new drugs bind to the cannabinoid receptors—which were initially named for their recognition of the tetrahydrocannabinol molecule found in marijuana—and produce some effects such as increased appetite or a sense of euphoria. However, the development of these drugs has been limited by the negative they elicit. In one high-profile case, a cannabinoid antagonist called Acomplia was designed to produce the opposite effects of cannabis. The drug was intended to treat obesity, but was pulled from the market when it was linked to increased suicide rates.

"Our lab works to design and make safer drugs with more controllable action," Makriyannis said. So with funding from the National Institute on Drug Abuse, he and his team set out to develop drugs that feature a timing mechanism that would allow the drug to be deactivated as soon as it has performed its function and be transformed to inactive products.

This timing mechanism, Makriyannis said, is relatively simple—it just takes some very smart and specific chemistry.

The new drugs are chemically modified to be biodegradable and susceptible to particular enzymes in the blood. The enzymes would recognize these drug's new chemical features and "chew them up" right at that spot. The time it takes for the enzymes to finish their action can be controlled, and the resulting byproducts from this enzymatic activity are completely safe, according to Makriyannis.

Additionally, the drugs' chemical modifications ensure they don't stick around in the body's fatty tissues as long, and are thus expelled much more quickly.

"When we started making these new compounds, we weren't sure if they would be successful," Makriyannis said. "But actually, they worked even better than we'd hoped." Not only do the compounds have fewer side effects than the original versions of the drugs, they are also more potent and effective.

While the drugs in the present research all target receptors in the endocannabinoid system, the approach can be applied to virtually any small-molecule drug, Makriyannis said.

"We are controlling the fate of a by just designing these molecules in a manner that allows them to act predictably," he said. "It's a general concept that we've used to make analgesic compounds that are safer and very potent, but the same concept could be used to make neuroprotective drugs or other therapeutic agents."

Explore further: Researchers discover a new anticancer compound using accelerated drug screening process

More information: "Controlled-Deactivation Cannabinergic Ligands." Rishi Sharma, Spyros P. Nikas, Carol A. Paronis, JodiAnne T. Wood, Aneetha Halikhedkar, Jason Jianxin Guo, Ganesh A. Thakur, Shashank Kulkarni, Othman Benchama, Jimit Girish Raghav, Roger S. Gifford, Torbjörn U. C. Järbe, Jack Bergman, and Alexandros Makriyannis. Journal of Medicinal Chemistry 2013 56 (24), 10142-10157. DOI: 10.1021/jm4016075

The report titled "C-Ring Cannabinoid Lactones: A Novel Cannabinergic Chemotype" is available online:

add to favorites email to friend print save as pdf

Related Stories

New discovery in quest for better drugs

Oct 14, 2013

Scientists have combined cutting edge computer modelling with pharmacology and medicinal chemistry to reveal new insights into how the body interacts with novel drug treatments, in research that could lead ...

An end to animal testing for drug discovery?

Mar 18, 2014

As some countries and companies roll out new rules to limit animal testing in pharmaceutical products designed for people, scientists are stepping in with a new way to test therapeutic drug candidates and determine drug safety ...

Molecular modelling to help create better, safer drugs

May 24, 2013

( —How our bodies break down the common drugs ibuprofen, diclofenac and warfarin is the subject of a new study from the University of Bristol, published in the Journal of the American Chemical So ...

Recommended for you

Chemical biologists find new halogenation enzyme

8 hours ago

Molecules containing carbon-halogen bonds are produced naturally across all kingdoms of life and constitute a large family of natural products with a broad range of biological activities. The presence of halogen substituents ...

Protein secrets of Ebola virus

14 hours ago

The current Ebola virus outbreak in West Africa, which has claimed more than 2000 lives, has highlighted the need for a deeper understanding of the molecular biology of the virus that could be critical in ...

Protein courtship revealed through chemist's lens

14 hours ago

Staying clear of diseases requires that the proteins in our cells cooperate with one another. But, it has been a well-guarded secret how tens of thousands of different proteins find the correct dancing partners ...

Decoding 'sweet codes' that determine protein fates

16 hours ago

We often experience difficulties in identifying the accurate shape of dynamic and fluctuating objects. This is especially the case in the nanoscale world of biomolecules. The research group lead by Professor Koichi Kato of ...

Conjecture on the lateral growth of Type I collagen fibrils

Sep 12, 2014

Whatever the origin and condition of extraction of type I collagen fibrils, in vitro as well as in vivo, the radii of their circular circular cross sections stay distributed in a range going from 50 to 100 nm for the most ...

User comments : 0